Literature DB >> 15698847

A Korean herbal medicine, Panax notoginseng, prevents liver fibrosis and hepatic microvascular dysfunction in rats.

Won-Hwan Park1, Soo-Kyung Lee, Cheorl-Ho Kim.   

Abstract

We assessed the prevention of hepatic fibrogenesis by water-extract of Panax notoginseng Buck F.H. Chen. (Arialiaceae) root (PNS) in Long-Evans rats with cinnamon coat color (LEC rats). LEC rats were divided into three groups A, fed on a basal diet (BD); B, fed on BD plus 1% PNS; and C), fed on BD plus 0.005% lycopene as a control. All rats were sacrificed at 26 weeks of age. The percentage of the total area involved by fibrosis was 1.46 +/- 0.47 in group A, 0.83 +/- 0.10 in B (P=0.0030, B vs A) and 0.91 +/- 0.45 in C (P=0.0035, C vs. A). The percentage of the total area that was stained for alpha-SMA was 0.56 +/- 0.34 in group A, 0.15 +/- 0.02 in B (P=0.0016, B vs. A and 0.11 +/- 0.01 in C (P=0.0025, C vs. A. In group B, malondialdehyde (MDA) in the liver was lower than in group C (P=0.007). In group C, the concentration of iron in the liver was lower than in group A (P=0.0053). Thus, PNS suppressed fibrogenesis through reduced generation of lipid peroxides. The mechanisms of this preventive effect of fibrogenesis with PNS were suggested to inhibit the stellate cell activity. Second objective of this study was to determine whether PNS affects hepatic microvascular dysfunction elicited by gut ischemia and reperfusion (I/R), since gut I/R causes hepatic microvascular dysfunction, and to investigate the role of nitric oxide (NO). Male Wistar rats were exposed to 30 min of gut ischemia followed by 60 min of reperfusion. Intravital microscopy was used to monitor the number of non-perfused sinusoids (NPS). In another set of experiments, PNS (1 g/kg per day intragastrically) was administered to rats for 7 days. In some experiments, dexamethasone (ST) (2 mg/kg per day intravenously) was administered. In control rats, gut I/R elicited increases in the number of NPS, and plasma TNF-alpha and ALT activities, and these changes were mitigated by the pretreatment with PNS. Pretreatment with an NO synthase inhibitor diminished the protective effects of PNS on the increase in NPS and plasma TNF-alpha levels, but not its effect on the increase in plasma ALT activities. Pretreatment with PNS increased plasma nitrite/nitrate levels. The responses caused by gut I/R were attenuated by the pretreatment with ST. Pretreatment with an NO synthase inhibitor did not affect the effect of ST. These results suggest that PNS attenuates the gut I/R-induced hepatic microvascular dysfunction and inflammatory responses such as TNF-alpha production in the early phase via enhancement of NO production, and sequential hepatocellular damage via its anti-inflammatory effect.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15698847     DOI: 10.1016/j.lfs.2004.07.030

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  16 in total

Review 1.  The use of selected nutrition supplements and complementary and alternative medicine in liver disease.

Authors:  A James Hanje; Brett Fortune; Ming Song; Daniell Hill; Craig McClain
Journal:  Nutr Clin Pract       Date:  2006-06       Impact factor: 3.080

2.  Protective effect of Panax ginseng against serum biochemical changes and apoptosis in kidney of rats treated with gentamicin sulphate.

Authors:  Yildiray Kalkan; Kubra Asena Terim Kapakin; Adem Kara; Tennur Atabay; Ali Karadeniz; Nejdet Simsek; Emre Karakus; Ismail Can; Serap Yildirim; Seckin Ozkanlar; Emin Sengul
Journal:  J Mol Histol       Date:  2012-04-10       Impact factor: 2.611

3.  Effect of notoginsenoside R1 on hepatic microcirculation disturbance induced by gut ischemia and reperfusion.

Authors:  Wei-Xing Chen; Fang Wang; Yu-Ying Liu; Qing-Jiang Zeng; Kai Sun; Xin Xue; Xiang Li; Ji-Ying Yang; Li-Hua An; Bai-He Hu; Jin-Hui Yang; Chuan-She Wang; Zhi-Xin Li; Lian-Yi Liu; Yan Li; Jun Zheng; Fu-Long Liao; Dong Han; Jing-Yu Fan; Jing-Yan Han
Journal:  World J Gastroenterol       Date:  2008-01-07       Impact factor: 5.742

4.  Nrf2 pathway activation contributes to anti-fibrosis effects of ginsenoside Rg1 in a rat model of alcohol- and CCl4-induced hepatic fibrosis.

Authors:  Jian-ping Li; Yan Gao; Shi-feng Chu; Zhao Zhang; Cong-yuan Xia; Zheng Mou; Xiu-yun Song; Wen-bin He; Xiao-feng Guo; Nai-hong Chen
Journal:  Acta Pharmacol Sin       Date:  2014-06-30       Impact factor: 6.150

5.  The protective effects of ginsenoside Rg1 against hypertension target-organ damage in spontaneously hypertensive rats.

Authors:  Hui Chen; Jun Yin; Yanpin Deng; Min Yang; Lingling Xu; Fukang Teng; Defang Li; Yufan Cheng; Sha Liu; Dong Wang; Tingting Zhang; Wanying Wu; Xuan Liu; Shuhong Guan; Baohong Jiang; Dean Guo
Journal:  BMC Complement Altern Med       Date:  2012-04-25       Impact factor: 3.659

6.  Panax notoginseng Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice.

Authors:  Kuen-Daw Tsai; Shu-Mei Yang; Jen-Chih Lee; Ho-Yiu Wong; Chuen-Ming Shih; Ting-Hui Lin; Min-Jen Tseng; Wei Chen
Journal:  Evid Based Complement Alternat Med       Date:  2011-03-06       Impact factor: 2.629

7.  Rapid but mild genoprotective effect on lymphocytic DNA with Panax notoginseng extract supplementation.

Authors:  Yim Tong Szeto; Loretta Kit Yee Lee
Journal:  J Intercult Ethnopharmacol       Date:  2014-08-26

8.  Effects of Borneol on Pharmacokinetics and Tissue Distribution of Notoginsenoside R1 and Ginsenosides Rg1 and Re in Panax notoginseng in Rabbits.

Authors:  Shixiang Wang; Weijin Zang; Xinfeng Zhao; Weiyi Feng; Ming Zhao; Xi He; Qinshe Liu; Xiaohui Zheng
Journal:  J Anal Methods Chem       Date:  2013-03-31       Impact factor: 2.193

9.  Biochemical and histopathological study in rats intoxicated with carbontetrachloride and treated with camel milk.

Authors:  Thnaian Althnaian; Ibrahim Albokhadaim; Sabry M El-Bahr
Journal:  Springerplus       Date:  2013-02-18

10.  Chinese medicines as a resource for liver fibrosis treatment.

Authors:  Yibin Feng; Kwok-Fan Cheung; Ning Wang; Ping Liu; Tadashi Nagamatsu; Yao Tong
Journal:  Chin Med       Date:  2009-08-20       Impact factor: 5.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.